Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Non-Immunotherapy Approaches for Relapsed or Refractory AML: An Update for 2024.

Acta haematologica - 1 Jan 2024

Buchrits Shira, Wolach Ofir

Abstract excerpt

BACKGROUND: Relapsed or refractory (R/R) acute myeloid leukemia (AML) is a challenging, high-risk, clinical scenario with a dismal outcome. Recent insights on the genetic, epigenetic, and metabolic events that drive clonal progression and the advent of novel therapies resulted in the incorporation of several new targeted therapies, alone or in combination, in the R/R setting with the aim of improving response...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents
Share to Combined Modality Therapy
Share to Leukemia, Myeloid, Acute

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mutation

Share to Tumor Microenvironment

Source

Identifiers

PMID: 37906979
DOI: 10.1159/000534897

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Non-Immunotherapy Approaches for Relapsed or Refractory AML: An Update for 2024.PMID 37906979Read ↗

Precision oncology to overcome resistance in R/R AML in children and adults requires combinations of cytotoxic, targeted, and immunological treatmentsSemantic proximity Read ↗

Targeted Therapies for the Evolving Molecular Landscape of Acute Myeloid LeukemiaSemantic proximity Read ↗

Recent advances in targeted therapies in acute myeloid leukemia.Semantic proximity Read ↗

Treatment of Acute Myeloid Leukemia in the Era of Genomics—Achievements and Persisting ChallengesSemantic proximity Read ↗

Acute myeloid leukemia: Treatment and research outlook for 2021 and the MD Anderson approach.Semantic proximity Read ↗

An overview of novel therapies in advanced clinical testing for acute myeloid leukemia.Semantic proximity Read ↗

Menin inhibitors for patients with relapsed/refractory acute myeloid leukemia (AML): a systematic review and meta-analysis.Semantic proximity Read ↗

Contemporary Management of Acute Myeloid Leukemia: A Review.Semantic proximity Read ↗

Emerging treatments in acute myeloid leukemia: current standards and unmet challenges.Semantic proximity Read ↗

Diagnosis and management of AML in adults: 2022 recommendations from an international expert panel on behalf of the ELN.Semantic proximity Read ↗

Experimental drugs in clinical trials for acute myeloid leukemia: innovations, trends, and opportunities.Semantic proximity Read ↗

An Overview of Targeted Therapies in Acute Myeloid LeukemiaSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.